ARIPIPRAZOLE
All strengths: General benefit; same patient cost rules
Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysPatient pays: program not supplied; amount cannot be determined.
Other products in the same Health Canada class (N05A, N05AX) — coverage varies; not interchangeable
- Brexpiprazole (Rexulti): general benefit
- Cariprazine (Vraylar): general benefit
- Paliperidone (Invega): general benefit
- Paliperidone palmitate (Invega Sustenna): general benefit
- Risperidone (Risperdal): general benefit, Not a benefit
- Asenapine (Saphris): general benefit
18 more in the class list below
Abilify · DIN 02322374 · 2mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: innoviCares lists Abilify (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up.
(innovicares.ca ↗)1 brand, same coverage
Abilify · DIN 02322374
Manufacturer: Otsuka Pharmaceutical Co. Ltd.; listing date 2011-10-25
Health Canada: Marketed since 2018-03-19 · brand ABILIFY · ATC N05AX12 ARIPIPRAZOLE · form Tablet · route Oral · ingredients ARIPIPRAZOLE 2 MG · company Otsuka pharmaceutical co ltd · schedule Prescription
Ministry pays: $0.8092 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80782 · Verify on the e-Formulary ↗ (DIN 02322374)
Source record
DIN 02322374: Abilify
Raw flags: sec3=Y
Item: 281608301; group id 478; item number 1210; lccId None; manufacturer id OTS
Source form: Tab; strength: 2mg
Recorded listing: General benefit
Source prices (unrounded): $3.3143; ministry $0.8092
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02322374
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80782
Therapeutic Notes (formulary)
Notes: Subject to the specific drug's product monograph, for the treatment of schizophrenia and related psychotic disorders after failure, intolerance or contraindication to at least one less expensive antipsychotic alternative.
Not indicated for the treatment of dementia or dementia-related behavioral problems in the elderly.
Prescribers should be informed and stay current with a drug's official indications in accordance with Health Canada's approved product monograph.
Interchangeable products
Apo-Aripiprazole · DIN 02471086 · $0.8092
Aripiprazole · DIN 02506688 · $0.8092
Aripiprazole · DIN 02534320 · $0.8092
Auro-Aripiprazole · DIN 02460025 · $0.8092
Jamp Aripiprazole · DIN 02553163 · $0.8092
Mint-Aripiprazole · DIN 02483556 · $0.8092
NRA-Aripiprazole · DIN 02472201 · $0.8092
PMS-Aripiprazole · DIN 02466635 · $0.8092
Sandoz Aripiprazole · DIN 02473658 · $0.8092
Teva-Aripiprazole · DIN 02464144 · $0.8092
Shortage status: discontinued (2021-02-28, reported by OTSUKA PHARMACEUTICAL CO LTD); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02322374
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Apo-Aripiprazole · DIN 02471086 · 2mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Apo-Aripiprazole · DIN 02471086
Manufacturer: Apotex Inc.; listing date 2018-06-29
Health Canada: Marketed since 2018-04-10 · brand APO-ARIPIPRAZOLE · ATC N05AX12 ARIPIPRAZOLE · form Tablet · route Oral · ingredients ARIPIPRAZOLE 2 MG · company Apotex inc · schedule Prescription
Apo-Aripiprazole: Formulary list price $0.8092/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.8092 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96019 · Verify on the e-Formulary ↗ (DIN 02471086)
Source record
DIN 02471086: Apo-Aripiprazole
Raw flags: sec3=Y
Item: 281608301; group id 478; item number 1210; lccId None; manufacturer id APX
Source form: Tab; strength: 2mg
Recorded listing: General benefit
Source prices (unrounded): $0.8092; ministry $0.8092
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02471086
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96019
Therapeutic Notes (formulary)
Notes: Subject to the specific drug's product monograph, for the treatment of schizophrenia and related psychotic disorders after failure, intolerance or contraindication to at least one less expensive antipsychotic alternative.
Not indicated for the treatment of dementia or dementia-related behavioral problems in the elderly.
Prescribers should be informed and stay current with a drug's official indications in accordance with Health Canada's approved product monograph.
Interchangeable products
Abilify · DIN 02322374 · $0.8092
Aripiprazole · DIN 02506688 · $0.8092
Aripiprazole · DIN 02534320 · $0.8092
Auro-Aripiprazole · DIN 02460025 · $0.8092
Jamp Aripiprazole · DIN 02553163 · $0.8092
Mint-Aripiprazole · DIN 02483556 · $0.8092
NRA-Aripiprazole · DIN 02472201 · $0.8092
PMS-Aripiprazole · DIN 02466635 · $0.8092
Sandoz Aripiprazole · DIN 02473658 · $0.8092
Teva-Aripiprazole · DIN 02464144 · $0.8092
Shortage status: resolved shortage (ended 2026-07-09); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02471086
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Aripiprazole · DIN 02506688 · 2mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Aripiprazole · DIN 02506688
Manufacturer: Sanis Health Inc.; listing date 2021-06-30
Health Canada: Marketed since 2021-04-23 · brand ARIPIPRAZOLE · ATC N05AX12 ARIPIPRAZOLE · form Tablet · route Oral · ingredients ARIPIPRAZOLE 2 MG · company Sanis health inc · schedule Prescription
Aripiprazole: Formulary list price $0.8092/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.8092 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99604 · Verify on the e-Formulary ↗ (DIN 02506688)
Source record
DIN 02506688: Aripiprazole
Raw flags: sec3=Y
Item: 281608301; group id 478; item number 1210; lccId None; manufacturer id SAI
Source form: Tab; strength: 2mg
Recorded listing: General benefit
Source prices (unrounded): $0.8092; ministry $0.8092
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02506688
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99604
Therapeutic Notes (formulary)
Notes: Subject to the specific drug's product monograph, for the treatment of schizophrenia and related psychotic disorders after failure, intolerance or contraindication to at least one less expensive antipsychotic alternative.
Not indicated for the treatment of dementia or dementia-related behavioral problems in the elderly.
Prescribers should be informed and stay current with a drug's official indications in accordance with Health Canada's approved product monograph.
Interchangeable products
Abilify · DIN 02322374 · $0.8092
Apo-Aripiprazole · DIN 02471086 · $0.8092
Aripiprazole · DIN 02534320 · $0.8092
Auro-Aripiprazole · DIN 02460025 · $0.8092
Jamp Aripiprazole · DIN 02553163 · $0.8092
Mint-Aripiprazole · DIN 02483556 · $0.8092
NRA-Aripiprazole · DIN 02472201 · $0.8092
PMS-Aripiprazole · DIN 02466635 · $0.8092
Sandoz Aripiprazole · DIN 02473658 · $0.8092
Teva-Aripiprazole · DIN 02464144 · $0.8092
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02506688
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Aripiprazole · DIN 02534320 · 2mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Aripiprazole · DIN 02534320
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2023-09-28
Health Canada: Marketed since 2023-07-20 · brand ARIPIPRAZOLE · ATC N05AX12 ARIPIPRAZOLE · form Tablet · route Oral · ingredients ARIPIPRAZOLE 2 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Aripiprazole: Formulary list price $0.8092/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.8092 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102326 · Verify on the e-Formulary ↗ (DIN 02534320)
Source record
DIN 02534320: Aripiprazole
Raw flags: sec3=Y
Item: 281608301; group id 478; item number 1210; lccId None; manufacturer id SIV
Source form: Tab; strength: 2mg
Recorded listing: General benefit
Source prices (unrounded): $0.8092; ministry $0.8092
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02534320
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102326
Therapeutic Notes (formulary)
Notes: Subject to the specific drug's product monograph, for the treatment of schizophrenia and related psychotic disorders after failure, intolerance or contraindication to at least one less expensive antipsychotic alternative.
Not indicated for the treatment of dementia or dementia-related behavioral problems in the elderly.
Prescribers should be informed and stay current with a drug's official indications in accordance with Health Canada's approved product monograph.
Interchangeable products
Abilify · DIN 02322374 · $0.8092
Apo-Aripiprazole · DIN 02471086 · $0.8092
Aripiprazole · DIN 02506688 · $0.8092
Auro-Aripiprazole · DIN 02460025 · $0.8092
Jamp Aripiprazole · DIN 02553163 · $0.8092
Mint-Aripiprazole · DIN 02483556 · $0.8092
NRA-Aripiprazole · DIN 02472201 · $0.8092
PMS-Aripiprazole · DIN 02466635 · $0.8092
Sandoz Aripiprazole · DIN 02473658 · $0.8092
Teva-Aripiprazole · DIN 02464144 · $0.8092
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02534320
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Auro-Aripiprazole · DIN 02460025 · 2mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Auro-Aripiprazole · DIN 02460025
Manufacturer: Auro Pharma Inc.; listing date 2018-09-27
Health Canada: Marketed since 2018-07-10 · brand AURO-ARIPIPRAZOLE · ATC N05AX12 ARIPIPRAZOLE · form Tablet · route Oral · ingredients ARIPIPRAZOLE 2 MG · company Auro pharma inc · schedule Prescription
Auro-Aripiprazole: Formulary list price $0.8092/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.8092 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94732 · Verify on the e-Formulary ↗ (DIN 02460025)
Source record
DIN 02460025: Auro-Aripiprazole
Raw flags: sec3=Y
Item: 281608301; group id 478; item number 1210; lccId None; manufacturer id AUR
Source form: Tab; strength: 2mg
Recorded listing: General benefit
Source prices (unrounded): $0.8092; ministry $0.8092
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02460025
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94732
Therapeutic Notes (formulary)
Notes: Subject to the specific drug's product monograph, for the treatment of schizophrenia and related psychotic disorders after failure, intolerance or contraindication to at least one less expensive antipsychotic alternative.
Not indicated for the treatment of dementia or dementia-related behavioral problems in the elderly.
Prescribers should be informed and stay current with a drug's official indications in accordance with Health Canada's approved product monograph.
Interchangeable products
Abilify · DIN 02322374 · $0.8092
Apo-Aripiprazole · DIN 02471086 · $0.8092
Aripiprazole · DIN 02506688 · $0.8092
Aripiprazole · DIN 02534320 · $0.8092
Jamp Aripiprazole · DIN 02553163 · $0.8092
Mint-Aripiprazole · DIN 02483556 · $0.8092
NRA-Aripiprazole · DIN 02472201 · $0.8092
PMS-Aripiprazole · DIN 02466635 · $0.8092
Sandoz Aripiprazole · DIN 02473658 · $0.8092
Teva-Aripiprazole · DIN 02464144 · $0.8092
Shortage status: resolved shortage (ended 2025-07-24); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02460025
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Jamp Aripiprazole · DIN 02553163 · 2mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Jamp Aripiprazole · DIN 02553163
Manufacturer: Jamp Pharma Corporation; listing date 2026-01-30
Health Canada: Marketed since 2025-11-27 · brand JAMP ARIPIPRAZOLE · ATC N05AX12 ARIPIPRAZOLE · form Tablet · route Oral · ingredients ARIPIPRAZOLE 2 MG · company Jamp pharma corporation · schedule Prescription
Jamp Aripiprazole: Formulary list price $0.8092/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.8092 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104212 · Verify on the e-Formulary ↗ (DIN 02553163)
Source record
DIN 02553163: Jamp Aripiprazole
Raw flags: sec3=Y
Item: 281608301; group id 478; item number 1210; lccId None; manufacturer id JPC
Source form: Tab; strength: 2mg
Recorded listing: General benefit
Source prices (unrounded): $0.8092; ministry $0.8092
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02553163
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104212
Therapeutic Notes (formulary)
Notes: Subject to the specific drug's product monograph, for the treatment of schizophrenia and related psychotic disorders after failure, intolerance or contraindication to at least one less expensive antipsychotic alternative.
Not indicated for the treatment of dementia or dementia-related behavioral problems in the elderly.
Prescribers should be informed and stay current with a drug's official indications in accordance with Health Canada's approved product monograph.
Interchangeable products
Abilify · DIN 02322374 · $0.8092
Apo-Aripiprazole · DIN 02471086 · $0.8092
Aripiprazole · DIN 02506688 · $0.8092
Aripiprazole · DIN 02534320 · $0.8092
Auro-Aripiprazole · DIN 02460025 · $0.8092
Mint-Aripiprazole · DIN 02483556 · $0.8092
NRA-Aripiprazole · DIN 02472201 · $0.8092
PMS-Aripiprazole · DIN 02466635 · $0.8092
Sandoz Aripiprazole · DIN 02473658 · $0.8092
Teva-Aripiprazole · DIN 02464144 · $0.8092
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02553163
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Mint-Aripiprazole · DIN 02483556 · 2mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Mint-Aripiprazole · DIN 02483556
Manufacturer: Mint Pharmaceuticals Inc.; listing date 2020-06-30
Health Canada: Marketed since 2020-05-04 · brand MINT-ARIPIPRAZOLE · ATC N05AX12 ARIPIPRAZOLE · form Tablet · route Oral · ingredients ARIPIPRAZOLE 2 MG · company Mint pharmaceuticals inc · schedule Prescription
Mint-Aripiprazole: Formulary list price $0.8092/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.8092 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97392 · Verify on the e-Formulary ↗ (DIN 02483556)
Source record
DIN 02483556: Mint-Aripiprazole
Raw flags: sec3=Y
Item: 281608301; group id 478; item number 1210; lccId None; manufacturer id MIN
Source form: Tab; strength: 2mg
Recorded listing: General benefit
Source prices (unrounded): $0.8092; ministry $0.8092
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02483556
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97392
Therapeutic Notes (formulary)
Notes: Subject to the specific drug's product monograph, for the treatment of schizophrenia and related psychotic disorders after failure, intolerance or contraindication to at least one less expensive antipsychotic alternative.
Not indicated for the treatment of dementia or dementia-related behavioral problems in the elderly.
Prescribers should be informed and stay current with a drug's official indications in accordance with Health Canada's approved product monograph.
Interchangeable products
Abilify · DIN 02322374 · $0.8092
Apo-Aripiprazole · DIN 02471086 · $0.8092
Aripiprazole · DIN 02506688 · $0.8092
Aripiprazole · DIN 02534320 · $0.8092
Auro-Aripiprazole · DIN 02460025 · $0.8092
Jamp Aripiprazole · DIN 02553163 · $0.8092
NRA-Aripiprazole · DIN 02472201 · $0.8092
PMS-Aripiprazole · DIN 02466635 · $0.8092
Sandoz Aripiprazole · DIN 02473658 · $0.8092
Teva-Aripiprazole · DIN 02464144 · $0.8092
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02483556
Shortage record checked 2026-09-13T08:10:21.292534+00:00
NRA-Aripiprazole · DIN 02472201 · 2mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
NRA-Aripiprazole · DIN 02472201
Manufacturer: Nora Pharma; listing date 2024-03-28
Health Canada: Marketed since 2024-01-23 · brand NRA-ARIPIPRAZOLE · ATC N05AX12 ARIPIPRAZOLE · form Tablet · route Oral · ingredients ARIPIPRAZOLE 2 MG · company Nora pharma inc · schedule Prescription
NRA-Aripiprazole: Formulary list price $0.8092/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.8092 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96153 · Verify on the e-Formulary ↗ (DIN 02472201)
Source record
DIN 02472201: NRA-Aripiprazole
Raw flags: sec3=Y
Item: 281608301; group id 478; item number 1210; lccId None; manufacturer id NRA
Source form: Tab; strength: 2mg
Recorded listing: General benefit
Source prices (unrounded): $0.8092; ministry $0.8092
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02472201
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96153
Therapeutic Notes (formulary)
Notes: Subject to the specific drug's product monograph, for the treatment of schizophrenia and related psychotic disorders after failure, intolerance or contraindication to at least one less expensive antipsychotic alternative.
Not indicated for the treatment of dementia or dementia-related behavioral problems in the elderly.
Prescribers should be informed and stay current with a drug's official indications in accordance with Health Canada's approved product monograph.
Interchangeable products
Abilify · DIN 02322374 · $0.8092
Apo-Aripiprazole · DIN 02471086 · $0.8092
Aripiprazole · DIN 02506688 · $0.8092
Aripiprazole · DIN 02534320 · $0.8092
Auro-Aripiprazole · DIN 02460025 · $0.8092
Jamp Aripiprazole · DIN 02553163 · $0.8092
Mint-Aripiprazole · DIN 02483556 · $0.8092
PMS-Aripiprazole · DIN 02466635 · $0.8092
Sandoz Aripiprazole · DIN 02473658 · $0.8092
Teva-Aripiprazole · DIN 02464144 · $0.8092
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02472201
Shortage record checked 2026-09-13T08:10:21.292534+00:00
PMS-Aripiprazole · DIN 02466635 · 2mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
PMS-Aripiprazole · DIN 02466635
Manufacturer: Pharmascience Inc.; listing date 2018-09-27
Health Canada: Marketed since 2018-07-10 · brand PMS-ARIPIPRAZOLE · ATC N05AX12 ARIPIPRAZOLE · form Tablet · route Oral · ingredients ARIPIPRAZOLE 2 MG · company Pharmascience inc · schedule Prescription
PMS-Aripiprazole: Formulary list price $0.8092/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.8092 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95498 · Verify on the e-Formulary ↗ (DIN 02466635)
Source record
DIN 02466635: PMS-Aripiprazole
Raw flags: sec3=Y
Item: 281608301; group id 478; item number 1210; lccId None; manufacturer id PMS
Source form: Tab; strength: 2mg
Recorded listing: General benefit
Source prices (unrounded): $0.8092; ministry $0.8092
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02466635
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95498
Therapeutic Notes (formulary)
Notes: Subject to the specific drug's product monograph, for the treatment of schizophrenia and related psychotic disorders after failure, intolerance or contraindication to at least one less expensive antipsychotic alternative.
Not indicated for the treatment of dementia or dementia-related behavioral problems in the elderly.
Prescribers should be informed and stay current with a drug's official indications in accordance with Health Canada's approved product monograph.
Interchangeable products
Abilify · DIN 02322374 · $0.8092
Apo-Aripiprazole · DIN 02471086 · $0.8092
Aripiprazole · DIN 02506688 · $0.8092
Aripiprazole · DIN 02534320 · $0.8092
Auro-Aripiprazole · DIN 02460025 · $0.8092
Jamp Aripiprazole · DIN 02553163 · $0.8092
Mint-Aripiprazole · DIN 02483556 · $0.8092
NRA-Aripiprazole · DIN 02472201 · $0.8092
Sandoz Aripiprazole · DIN 02473658 · $0.8092
Teva-Aripiprazole · DIN 02464144 · $0.8092
Shortage status: resolved shortage (ended 2019-09-09); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02466635
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Sandoz Aripiprazole · DIN 02473658 · 2mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Sandoz Aripiprazole · DIN 02473658
Manufacturer: Sandoz Canada Inc.; listing date 2018-09-27
Health Canada: Marketed since 2018-07-10 · brand SANDOZ ARIPIPRAZOLE · ATC N05AX12 ARIPIPRAZOLE · form Tablet · route Oral · ingredients ARIPIPRAZOLE 2 MG · company Sandoz canada incorporated · schedule Prescription
Sandoz Aripiprazole: Formulary list price $0.8092/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.8092 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96304 · Verify on the e-Formulary ↗ (DIN 02473658)
Source record
DIN 02473658: Sandoz Aripiprazole
Raw flags: sec3=Y
Item: 281608301; group id 478; item number 1210; lccId None; manufacturer id SDZ
Source form: Tab; strength: 2mg
Recorded listing: General benefit
Source prices (unrounded): $0.8092; ministry $0.8092
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02473658
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96304
Therapeutic Notes (formulary)
Notes: Subject to the specific drug's product monograph, for the treatment of schizophrenia and related psychotic disorders after failure, intolerance or contraindication to at least one less expensive antipsychotic alternative.
Not indicated for the treatment of dementia or dementia-related behavioral problems in the elderly.
Prescribers should be informed and stay current with a drug's official indications in accordance with Health Canada's approved product monograph.
Interchangeable products
Abilify · DIN 02322374 · $0.8092
Apo-Aripiprazole · DIN 02471086 · $0.8092
Aripiprazole · DIN 02506688 · $0.8092
Aripiprazole · DIN 02534320 · $0.8092
Auro-Aripiprazole · DIN 02460025 · $0.8092
Jamp Aripiprazole · DIN 02553163 · $0.8092
Mint-Aripiprazole · DIN 02483556 · $0.8092
NRA-Aripiprazole · DIN 02472201 · $0.8092
PMS-Aripiprazole · DIN 02466635 · $0.8092
Teva-Aripiprazole · DIN 02464144 · $0.8092
Shortage status: resolved shortage (ended 2021-01-19); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02473658
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Abilify · DIN 02322382 · 5mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: innoviCares lists Abilify (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up.
(innovicares.ca ↗)1 brand, same coverage
Abilify · DIN 02322382
Manufacturer: Otsuka Pharmaceutical Co. Ltd.; listing date 2011-10-25
Health Canada: Marketed since 2018-04-04 · brand ABILIFY · ATC N05AX12 ARIPIPRAZOLE · form Tablet · route Oral · ingredients ARIPIPRAZOLE 5 MG · company Otsuka pharmaceutical co ltd · schedule Prescription
Ministry pays: $0.9046 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80783 · Verify on the e-Formulary ↗ (DIN 02322382)
Source record
DIN 02322382: Abilify
Raw flags: sec3=Y
Item: 281608302; group id 478; item number 1211; lccId None; manufacturer id OTS
Source form: Tab; strength: 5mg
Recorded listing: General benefit
Source prices (unrounded): $3.7052; ministry $0.9046
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02322382
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80783
Therapeutic Notes (formulary)
Notes: Subject to the specific drug's product monograph, for the treatment of schizophrenia and related psychotic disorders after failure, intolerance or contraindication to at least one less expensive antipsychotic alternative.
Not indicated for the treatment of dementia or dementia-related behavioral problems in the elderly.
Prescribers should be informed and stay current with a drug's official indications in accordance with Health Canada's approved product monograph.
Interchangeable products
Apo-Aripiprazole · DIN 02471094 · $0.9046
Aripiprazole · DIN 02506718 · $0.9046
Aripiprazole · DIN 02534339 · $0.9046
Auro-Aripiprazole · DIN 02460033 · $0.9046
Jamp Aripiprazole · DIN 02553171 · $0.9046
Mint-Aripiprazole · DIN 02483564 · $0.9046
NRA-Aripiprazole · DIN 02472228 · $0.9046
PMS-Aripiprazole · DIN 02466643 · $0.9046
Sandoz Aripiprazole · DIN 02473666 · $0.9046
Teva-Aripiprazole · DIN 02464152 · $0.9046
Shortage status: discontinued (2021-04-30, reported by OTSUKA PHARMACEUTICAL CO LTD); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02322382
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Apo-Aripiprazole · DIN 02471094 · 5mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Apo-Aripiprazole · DIN 02471094
Manufacturer: Apotex Inc.; listing date 2018-06-29
Health Canada: Marketed since 2018-04-10 · brand APO-ARIPIPRAZOLE · ATC N05AX12 ARIPIPRAZOLE · form Tablet · route Oral · ingredients ARIPIPRAZOLE 5 MG · company Apotex inc · schedule Prescription
Apo-Aripiprazole: Formulary list price $0.9046/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.9046 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96020 · Verify on the e-Formulary ↗ (DIN 02471094)
Source record
DIN 02471094: Apo-Aripiprazole
Raw flags: sec3=Y
Item: 281608302; group id 478; item number 1211; lccId None; manufacturer id APX
Source form: Tab; strength: 5mg
Recorded listing: General benefit
Source prices (unrounded): $0.9046; ministry $0.9046
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02471094
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96020
Therapeutic Notes (formulary)
Notes: Subject to the specific drug's product monograph, for the treatment of schizophrenia and related psychotic disorders after failure, intolerance or contraindication to at least one less expensive antipsychotic alternative.
Not indicated for the treatment of dementia or dementia-related behavioral problems in the elderly.
Prescribers should be informed and stay current with a drug's official indications in accordance with Health Canada's approved product monograph.
Interchangeable products
Abilify · DIN 02322382 · $0.9046
Aripiprazole · DIN 02506718 · $0.9046
Aripiprazole · DIN 02534339 · $0.9046
Auro-Aripiprazole · DIN 02460033 · $0.9046
Jamp Aripiprazole · DIN 02553171 · $0.9046
Mint-Aripiprazole · DIN 02483564 · $0.9046
NRA-Aripiprazole · DIN 02472228 · $0.9046
PMS-Aripiprazole · DIN 02466643 · $0.9046
Sandoz Aripiprazole · DIN 02473666 · $0.9046
Teva-Aripiprazole · DIN 02464152 · $0.9046
Shortage status: shortage reported ended 2026-07-02 (report last updated 2026-07-02); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02471094
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Aripiprazole · DIN 02506718 · 5mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Aripiprazole · DIN 02506718
Manufacturer: Sanis Health Inc.; listing date 2021-06-30
Health Canada: Marketed since 2021-04-23 · brand ARIPIPRAZOLE · ATC N05AX12 ARIPIPRAZOLE · form Tablet · route Oral · ingredients ARIPIPRAZOLE 5 MG · company Sanis health inc · schedule Prescription
Aripiprazole: Formulary list price $0.9046/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.9046 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99606 · Verify on the e-Formulary ↗ (DIN 02506718)
Source record
DIN 02506718: Aripiprazole
Raw flags: sec3=Y
Item: 281608302; group id 478; item number 1211; lccId None; manufacturer id SAI
Source form: Tab; strength: 5mg
Recorded listing: General benefit
Source prices (unrounded): $0.9046; ministry $0.9046
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02506718
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99606
Therapeutic Notes (formulary)
Notes: Subject to the specific drug's product monograph, for the treatment of schizophrenia and related psychotic disorders after failure, intolerance or contraindication to at least one less expensive antipsychotic alternative.
Not indicated for the treatment of dementia or dementia-related behavioral problems in the elderly.
Prescribers should be informed and stay current with a drug's official indications in accordance with Health Canada's approved product monograph.
Interchangeable products
Abilify · DIN 02322382 · $0.9046
Apo-Aripiprazole · DIN 02471094 · $0.9046
Aripiprazole · DIN 02534339 · $0.9046
Auro-Aripiprazole · DIN 02460033 · $0.9046
Jamp Aripiprazole · DIN 02553171 · $0.9046
Mint-Aripiprazole · DIN 02483564 · $0.9046
NRA-Aripiprazole · DIN 02472228 · $0.9046
PMS-Aripiprazole · DIN 02466643 · $0.9046
Sandoz Aripiprazole · DIN 02473666 · $0.9046
Teva-Aripiprazole · DIN 02464152 · $0.9046
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02506718
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Aripiprazole · DIN 02534339 · 5mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Aripiprazole · DIN 02534339
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2023-09-28
Health Canada: Marketed since 2023-07-20 · brand ARIPIPRAZOLE · ATC N05AX12 ARIPIPRAZOLE · form Tablet · route Oral · ingredients ARIPIPRAZOLE 5 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Aripiprazole: Formulary list price $0.9046/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.9046 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102327 · Verify on the e-Formulary ↗ (DIN 02534339)
Source record
DIN 02534339: Aripiprazole
Raw flags: sec3=Y
Item: 281608302; group id 478; item number 1211; lccId None; manufacturer id SIV
Source form: Tab; strength: 5mg
Recorded listing: General benefit
Source prices (unrounded): $0.9046; ministry $0.9046
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02534339
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102327
Therapeutic Notes (formulary)
Notes: Subject to the specific drug's product monograph, for the treatment of schizophrenia and related psychotic disorders after failure, intolerance or contraindication to at least one less expensive antipsychotic alternative.
Not indicated for the treatment of dementia or dementia-related behavioral problems in the elderly.
Prescribers should be informed and stay current with a drug's official indications in accordance with Health Canada's approved product monograph.
Interchangeable products
Abilify · DIN 02322382 · $0.9046
Apo-Aripiprazole · DIN 02471094 · $0.9046
Aripiprazole · DIN 02506718 · $0.9046
Auro-Aripiprazole · DIN 02460033 · $0.9046
Jamp Aripiprazole · DIN 02553171 · $0.9046
Mint-Aripiprazole · DIN 02483564 · $0.9046
NRA-Aripiprazole · DIN 02472228 · $0.9046
PMS-Aripiprazole · DIN 02466643 · $0.9046
Sandoz Aripiprazole · DIN 02473666 · $0.9046
Teva-Aripiprazole · DIN 02464152 · $0.9046
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02534339
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Auro-Aripiprazole · DIN 02460033 · 5mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Auro-Aripiprazole · DIN 02460033
Manufacturer: Auro Pharma Inc.; listing date 2018-09-27
Health Canada: Marketed since 2018-07-10 · brand AURO-ARIPIPRAZOLE · ATC N05AX12 ARIPIPRAZOLE · form Tablet · route Oral · ingredients ARIPIPRAZOLE 5 MG · company Auro pharma inc · schedule Prescription
Auro-Aripiprazole: Formulary list price $0.9046/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.9046 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94733 · Verify on the e-Formulary ↗ (DIN 02460033)
Source record
DIN 02460033: Auro-Aripiprazole
Raw flags: sec3=Y
Item: 281608302; group id 478; item number 1211; lccId None; manufacturer id AUR
Source form: Tab; strength: 5mg
Recorded listing: General benefit
Source prices (unrounded): $0.9046; ministry $0.9046
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02460033
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94733
Therapeutic Notes (formulary)
Notes: Subject to the specific drug's product monograph, for the treatment of schizophrenia and related psychotic disorders after failure, intolerance or contraindication to at least one less expensive antipsychotic alternative.
Not indicated for the treatment of dementia or dementia-related behavioral problems in the elderly.
Prescribers should be informed and stay current with a drug's official indications in accordance with Health Canada's approved product monograph.
Interchangeable products
Abilify · DIN 02322382 · $0.9046
Apo-Aripiprazole · DIN 02471094 · $0.9046
Aripiprazole · DIN 02506718 · $0.9046
Aripiprazole · DIN 02534339 · $0.9046
Jamp Aripiprazole · DIN 02553171 · $0.9046
Mint-Aripiprazole · DIN 02483564 · $0.9046
NRA-Aripiprazole · DIN 02472228 · $0.9046
PMS-Aripiprazole · DIN 02466643 · $0.9046
Sandoz Aripiprazole · DIN 02473666 · $0.9046
Teva-Aripiprazole · DIN 02464152 · $0.9046
Shortage status: resolved shortage (ended 2025-03-17); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02460033
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Jamp Aripiprazole · DIN 02553171 · 5mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Jamp Aripiprazole · DIN 02553171
Manufacturer: Jamp Pharma Corporation; listing date 2026-01-30
Health Canada: Marketed since 2025-11-27 · brand JAMP ARIPIPRAZOLE · ATC N05AX12 ARIPIPRAZOLE · form Tablet · route Oral · ingredients ARIPIPRAZOLE 5 MG · company Jamp pharma corporation · schedule Prescription
Jamp Aripiprazole: Formulary list price $0.9046/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.9046 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104213 · Verify on the e-Formulary ↗ (DIN 02553171)
Source record
DIN 02553171: Jamp Aripiprazole
Raw flags: sec3=Y
Item: 281608302; group id 478; item number 1211; lccId None; manufacturer id JPC
Source form: Tab; strength: 5mg
Recorded listing: General benefit
Source prices (unrounded): $0.9046; ministry $0.9046
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02553171
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104213
Therapeutic Notes (formulary)
Notes: Subject to the specific drug's product monograph, for the treatment of schizophrenia and related psychotic disorders after failure, intolerance or contraindication to at least one less expensive antipsychotic alternative.
Not indicated for the treatment of dementia or dementia-related behavioral problems in the elderly.
Prescribers should be informed and stay current with a drug's official indications in accordance with Health Canada's approved product monograph.
Interchangeable products
Abilify · DIN 02322382 · $0.9046
Apo-Aripiprazole · DIN 02471094 · $0.9046
Aripiprazole · DIN 02506718 · $0.9046
Aripiprazole · DIN 02534339 · $0.9046
Auro-Aripiprazole · DIN 02460033 · $0.9046
Mint-Aripiprazole · DIN 02483564 · $0.9046
NRA-Aripiprazole · DIN 02472228 · $0.9046
PMS-Aripiprazole · DIN 02466643 · $0.9046
Sandoz Aripiprazole · DIN 02473666 · $0.9046
Teva-Aripiprazole · DIN 02464152 · $0.9046
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02553171
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Mint-Aripiprazole · DIN 02483564 · 5mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Mint-Aripiprazole · DIN 02483564
Manufacturer: Mint Pharmaceuticals Inc.; listing date 2020-06-30
Health Canada: Marketed since 2020-04-14 · brand MINT-ARIPIPRAZOLE · ATC N05AX12 ARIPIPRAZOLE · form Tablet · route Oral · ingredients ARIPIPRAZOLE 5 MG · company Mint pharmaceuticals inc · schedule Prescription
Mint-Aripiprazole: Formulary list price $0.9046/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.9046 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97393 · Verify on the e-Formulary ↗ (DIN 02483564)
Source record
DIN 02483564: Mint-Aripiprazole
Raw flags: sec3=Y
Item: 281608302; group id 478; item number 1211; lccId None; manufacturer id MIN
Source form: Tab; strength: 5mg
Recorded listing: General benefit
Source prices (unrounded): $0.9046; ministry $0.9046
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02483564
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97393
Therapeutic Notes (formulary)
Notes: Subject to the specific drug's product monograph, for the treatment of schizophrenia and related psychotic disorders after failure, intolerance or contraindication to at least one less expensive antipsychotic alternative.
Not indicated for the treatment of dementia or dementia-related behavioral problems in the elderly.
Prescribers should be informed and stay current with a drug's official indications in accordance with Health Canada's approved product monograph.
Interchangeable products
Abilify · DIN 02322382 · $0.9046
Apo-Aripiprazole · DIN 02471094 · $0.9046
Aripiprazole · DIN 02506718 · $0.9046
Aripiprazole · DIN 02534339 · $0.9046
Auro-Aripiprazole · DIN 02460033 · $0.9046
Jamp Aripiprazole · DIN 02553171 · $0.9046
NRA-Aripiprazole · DIN 02472228 · $0.9046
PMS-Aripiprazole · DIN 02466643 · $0.9046
Sandoz Aripiprazole · DIN 02473666 · $0.9046
Teva-Aripiprazole · DIN 02464152 · $0.9046
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02483564
Shortage record checked 2026-09-13T08:10:21.292534+00:00
NRA-Aripiprazole · DIN 02472228 · 5mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
NRA-Aripiprazole · DIN 02472228
Manufacturer: Nora Pharma; listing date 2024-03-28
Health Canada: Marketed since 2024-01-23 · brand NRA-ARIPIPRAZOLE · ATC N05AX12 ARIPIPRAZOLE · form Tablet · route Oral · ingredients ARIPIPRAZOLE 5 MG · company Nora pharma inc · schedule Prescription
NRA-Aripiprazole: Formulary list price $0.9046/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.9046 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96154 · Verify on the e-Formulary ↗ (DIN 02472228)
Source record
DIN 02472228: NRA-Aripiprazole
Raw flags: sec3=Y
Item: 281608302; group id 478; item number 1211; lccId None; manufacturer id NRA
Source form: Tab; strength: 5mg
Recorded listing: General benefit
Source prices (unrounded): $0.9046; ministry $0.9046
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02472228
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96154
Therapeutic Notes (formulary)
Notes: Subject to the specific drug's product monograph, for the treatment of schizophrenia and related psychotic disorders after failure, intolerance or contraindication to at least one less expensive antipsychotic alternative.
Not indicated for the treatment of dementia or dementia-related behavioral problems in the elderly.
Prescribers should be informed and stay current with a drug's official indications in accordance with Health Canada's approved product monograph.
Interchangeable products
Abilify · DIN 02322382 · $0.9046
Apo-Aripiprazole · DIN 02471094 · $0.9046
Aripiprazole · DIN 02506718 · $0.9046
Aripiprazole · DIN 02534339 · $0.9046
Auro-Aripiprazole · DIN 02460033 · $0.9046
Jamp Aripiprazole · DIN 02553171 · $0.9046
Mint-Aripiprazole · DIN 02483564 · $0.9046
PMS-Aripiprazole · DIN 02466643 · $0.9046
Sandoz Aripiprazole · DIN 02473666 · $0.9046
Teva-Aripiprazole · DIN 02464152 · $0.9046
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02472228
Shortage record checked 2026-09-13T08:10:21.292534+00:00
PMS-Aripiprazole · DIN 02466643 · 5mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
PMS-Aripiprazole · DIN 02466643
Manufacturer: Pharmascience Inc.; listing date 2018-09-27
Health Canada: Marketed since 2018-07-10 · brand PMS-ARIPIPRAZOLE · ATC N05AX12 ARIPIPRAZOLE · form Tablet · route Oral · ingredients ARIPIPRAZOLE 5 MG · company Pharmascience inc · schedule Prescription
PMS-Aripiprazole: Formulary list price $0.9046/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.9046 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95499 · Verify on the e-Formulary ↗ (DIN 02466643)
Source record
DIN 02466643: PMS-Aripiprazole
Raw flags: sec3=Y
Item: 281608302; group id 478; item number 1211; lccId None; manufacturer id PMS
Source form: Tab; strength: 5mg
Recorded listing: General benefit
Source prices (unrounded): $0.9046; ministry $0.9046
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02466643
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95499
Therapeutic Notes (formulary)
Notes: Subject to the specific drug's product monograph, for the treatment of schizophrenia and related psychotic disorders after failure, intolerance or contraindication to at least one less expensive antipsychotic alternative.
Not indicated for the treatment of dementia or dementia-related behavioral problems in the elderly.
Prescribers should be informed and stay current with a drug's official indications in accordance with Health Canada's approved product monograph.
Interchangeable products
Abilify · DIN 02322382 · $0.9046
Apo-Aripiprazole · DIN 02471094 · $0.9046
Aripiprazole · DIN 02506718 · $0.9046
Aripiprazole · DIN 02534339 · $0.9046
Auro-Aripiprazole · DIN 02460033 · $0.9046
Jamp Aripiprazole · DIN 02553171 · $0.9046
Mint-Aripiprazole · DIN 02483564 · $0.9046
NRA-Aripiprazole · DIN 02472228 · $0.9046
Sandoz Aripiprazole · DIN 02473666 · $0.9046
Teva-Aripiprazole · DIN 02464152 · $0.9046
Shortage status: resolved shortage (ended 2020-03-09); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02466643
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Sandoz Aripiprazole · DIN 02473666 · 5mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Sandoz Aripiprazole · DIN 02473666
Manufacturer: Sandoz Canada Inc.; listing date 2018-09-27
Health Canada: Marketed since 2018-07-10 · brand SANDOZ ARIPIPRAZOLE · ATC N05AX12 ARIPIPRAZOLE · form Tablet · route Oral · ingredients ARIPIPRAZOLE 5 MG · company Sandoz canada incorporated · schedule Prescription
Sandoz Aripiprazole: Formulary list price $0.9046/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.9046 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96305 · Verify on the e-Formulary ↗ (DIN 02473666)
Source record
DIN 02473666: Sandoz Aripiprazole
Raw flags: sec3=Y
Item: 281608302; group id 478; item number 1211; lccId None; manufacturer id SDZ
Source form: Tab; strength: 5mg
Recorded listing: General benefit
Source prices (unrounded): $0.9046; ministry $0.9046
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02473666
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96305
Therapeutic Notes (formulary)
Notes: Subject to the specific drug's product monograph, for the treatment of schizophrenia and related psychotic disorders after failure, intolerance or contraindication to at least one less expensive antipsychotic alternative.
Not indicated for the treatment of dementia or dementia-related behavioral problems in the elderly.
Prescribers should be informed and stay current with a drug's official indications in accordance with Health Canada's approved product monograph.
Interchangeable products
Abilify · DIN 02322382 · $0.9046
Apo-Aripiprazole · DIN 02471094 · $0.9046
Aripiprazole · DIN 02506718 · $0.9046
Aripiprazole · DIN 02534339 · $0.9046
Auro-Aripiprazole · DIN 02460033 · $0.9046
Jamp Aripiprazole · DIN 02553171 · $0.9046
Mint-Aripiprazole · DIN 02483564 · $0.9046
NRA-Aripiprazole · DIN 02472228 · $0.9046
PMS-Aripiprazole · DIN 02466643 · $0.9046
Teva-Aripiprazole · DIN 02464152 · $0.9046
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02473666
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Abilify · DIN 02322390 · 10mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: innoviCares lists Abilify (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up.
(innovicares.ca ↗)1 brand, same coverage
Abilify · DIN 02322390
Manufacturer: Otsuka Pharmaceutical Co. Ltd.; listing date 2011-10-25
Health Canada: Marketed since 2018-07-13 · brand ABILIFY · ATC N05AX12 ARIPIPRAZOLE · form Tablet · route Oral · ingredients ARIPIPRAZOLE 10 MG · company Otsuka pharmaceutical co ltd · schedule Prescription
Ministry pays: $1.0754 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80784 · Verify on the e-Formulary ↗ (DIN 02322390)
Source record
DIN 02322390: Abilify
Raw flags: sec3=Y
Item: 281608303; group id 478; item number 1212; lccId None; manufacturer id OTS
Source form: Tab; strength: 10mg
Recorded listing: General benefit
Source prices (unrounded): $4.4049; ministry $1.0754
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02322390
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80784
Therapeutic Notes (formulary)
Notes: Subject to the specific drug's product monograph, for the treatment of schizophrenia and related psychotic disorders after failure, intolerance or contraindication to at least one less expensive antipsychotic alternative.
Not indicated for the treatment of dementia or dementia-related behavioral problems in the elderly.
Prescribers should be informed and stay current with a drug's official indications in accordance with Health Canada's approved product monograph.
Interchangeable products
Apo-Aripiprazole · DIN 02471108 · $1.0754
Aripiprazole · DIN 02506726 · $1.0754
Aripiprazole · DIN 02534347 · $1.0754
Auro-Aripiprazole · DIN 02460041 · $1.0754
Jamp Aripiprazole · DIN 02553198 · $1.0754
Mint-Aripiprazole · DIN 02483572 · $1.0754
NRA-Aripiprazole · DIN 02472244 · $1.0754
PMS-Aripiprazole · DIN 02466651 · $1.0754
Sandoz Aripiprazole · DIN 02473674 · $1.0754
Teva-Aripiprazole · DIN 02464160 · $1.0754
Shortage status: discontinued (2021-04-30, reported by OTSUKA PHARMACEUTICAL CO LTD); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02322390
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Apo-Aripiprazole · DIN 02471108 · 10mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Apo-Aripiprazole · DIN 02471108
Manufacturer: Apotex Inc.; listing date 2018-06-29
Health Canada: Marketed since 2018-04-10 · brand APO-ARIPIPRAZOLE · ATC N05AX12 ARIPIPRAZOLE · form Tablet · route Oral · ingredients ARIPIPRAZOLE 10 MG · company Apotex inc · schedule Prescription
Apo-Aripiprazole: Formulary list price $1.0754/unit (unit not stated in source; not the patient's cost)
Ministry pays: $1.0754 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96021 · Verify on the e-Formulary ↗ (DIN 02471108)
Source record
DIN 02471108: Apo-Aripiprazole
Raw flags: sec3=Y
Item: 281608303; group id 478; item number 1212; lccId None; manufacturer id APX
Source form: Tab; strength: 10mg
Recorded listing: General benefit
Source prices (unrounded): $1.0754; ministry $1.0754
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02471108
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96021
Therapeutic Notes (formulary)
Notes: Subject to the specific drug's product monograph, for the treatment of schizophrenia and related psychotic disorders after failure, intolerance or contraindication to at least one less expensive antipsychotic alternative.
Not indicated for the treatment of dementia or dementia-related behavioral problems in the elderly.
Prescribers should be informed and stay current with a drug's official indications in accordance with Health Canada's approved product monograph.
Interchangeable products
Abilify · DIN 02322390 · $1.0754
Aripiprazole · DIN 02506726 · $1.0754
Aripiprazole · DIN 02534347 · $1.0754
Auro-Aripiprazole · DIN 02460041 · $1.0754
Jamp Aripiprazole · DIN 02553198 · $1.0754
Mint-Aripiprazole · DIN 02483572 · $1.0754
NRA-Aripiprazole · DIN 02472244 · $1.0754
PMS-Aripiprazole · DIN 02466651 · $1.0754
Sandoz Aripiprazole · DIN 02473674 · $1.0754
Teva-Aripiprazole · DIN 02464160 · $1.0754
Shortage status: shortage reported ended 2026-07-02 (report last updated 2026-07-02); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02471108
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Aripiprazole · DIN 02506726 · 10mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Aripiprazole · DIN 02506726
Manufacturer: Sanis Health Inc.; listing date 2021-06-30
Health Canada: Marketed since 2021-04-23 · brand ARIPIPRAZOLE · ATC N05AX12 ARIPIPRAZOLE · form Tablet · route Oral · ingredients ARIPIPRAZOLE 10 MG · company Sanis health inc · schedule Prescription
Aripiprazole: Formulary list price $1.0754/unit (unit not stated in source; not the patient's cost)
Ministry pays: $1.0754 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99607 · Verify on the e-Formulary ↗ (DIN 02506726)
Source record
DIN 02506726: Aripiprazole
Raw flags: sec3=Y
Item: 281608303; group id 478; item number 1212; lccId None; manufacturer id SAI
Source form: Tab; strength: 10mg
Recorded listing: General benefit
Source prices (unrounded): $1.0754; ministry $1.0754
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02506726
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99607
Therapeutic Notes (formulary)
Notes: Subject to the specific drug's product monograph, for the treatment of schizophrenia and related psychotic disorders after failure, intolerance or contraindication to at least one less expensive antipsychotic alternative.
Not indicated for the treatment of dementia or dementia-related behavioral problems in the elderly.
Prescribers should be informed and stay current with a drug's official indications in accordance with Health Canada's approved product monograph.
Interchangeable products
Abilify · DIN 02322390 · $1.0754
Apo-Aripiprazole · DIN 02471108 · $1.0754
Aripiprazole · DIN 02534347 · $1.0754
Auro-Aripiprazole · DIN 02460041 · $1.0754
Jamp Aripiprazole · DIN 02553198 · $1.0754
Mint-Aripiprazole · DIN 02483572 · $1.0754
NRA-Aripiprazole · DIN 02472244 · $1.0754
PMS-Aripiprazole · DIN 02466651 · $1.0754
Sandoz Aripiprazole · DIN 02473674 · $1.0754
Teva-Aripiprazole · DIN 02464160 · $1.0754
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02506726
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Aripiprazole · DIN 02534347 · 10mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Aripiprazole · DIN 02534347
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2023-09-28
Health Canada: Marketed since 2023-07-20 · brand ARIPIPRAZOLE · ATC N05AX12 ARIPIPRAZOLE · form Tablet · route Oral · ingredients ARIPIPRAZOLE 10 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Aripiprazole: Formulary list price $1.0754/unit (unit not stated in source; not the patient's cost)
Ministry pays: $1.0754 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102328 · Verify on the e-Formulary ↗ (DIN 02534347)
Source record
DIN 02534347: Aripiprazole
Raw flags: sec3=Y
Item: 281608303; group id 478; item number 1212; lccId None; manufacturer id SIV
Source form: Tab; strength: 10mg
Recorded listing: General benefit
Source prices (unrounded): $1.0754; ministry $1.0754
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02534347
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102328
Therapeutic Notes (formulary)
Notes: Subject to the specific drug's product monograph, for the treatment of schizophrenia and related psychotic disorders after failure, intolerance or contraindication to at least one less expensive antipsychotic alternative.
Not indicated for the treatment of dementia or dementia-related behavioral problems in the elderly.
Prescribers should be informed and stay current with a drug's official indications in accordance with Health Canada's approved product monograph.
Interchangeable products
Abilify · DIN 02322390 · $1.0754
Apo-Aripiprazole · DIN 02471108 · $1.0754
Aripiprazole · DIN 02506726 · $1.0754
Auro-Aripiprazole · DIN 02460041 · $1.0754
Jamp Aripiprazole · DIN 02553198 · $1.0754
Mint-Aripiprazole · DIN 02483572 · $1.0754
NRA-Aripiprazole · DIN 02472244 · $1.0754
PMS-Aripiprazole · DIN 02466651 · $1.0754
Sandoz Aripiprazole · DIN 02473674 · $1.0754
Teva-Aripiprazole · DIN 02464160 · $1.0754
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02534347
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (28:16:08 Tranquilizers) and how they are covered
Matched class: 28:16:08 Tranquilizers
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Covered without a code on the Ontario formulary: ASENAPINE, BREXPIPRAZOLE, CARIPRAZINE, FLUPENTIXOL DECANOATE, FLUPENTIXOL DIHYDROCHLORIDE, PALIPERIDONE, PALIPERIDONE PALMITATE, PERICYAZINE, PIMOZIDE, ZIPRASIDONE HCL MONOHYDRATE, ZUCLOPENTHIXOL DECANOATE, ZUCLOPENTHIXOL DIHYDROCHLORIDE
Some products covered without a code (check the product listing): ALPRAZOLAM, BROMAZEPAM, CHLORDIAZEPOXIDE, CHLORPROMAZINE, CLORAZEPATE DIPOTASSIUM, DIAZEPAM, FLUPHENAZINE HCL, HALOPERIDOL, HALOPERIDOL DECANOATE, LORAZEPAM, LOXAPINE SUCCINATE, LURASIDONE HYDROCHLORIDE, OLANZAPINE, OXAZEPAM, PERPHENAZINE, PROCHLORPERAZINE, QUETIAPINE, RISPERIDONE, TRIFLUOPERAZINE
28:16:08 Tranquilizers
· 6 products · General benefit · strengths: 0.25mg, 0.5mg, 1mg, 2mg, 3mg, 4mg · Tab
· 4 products · General benefit · strengths: 1.5mg, 3mg, 4.5mg, 6mg · Cap
· 3 products · General benefit · strengths: 3mg, 6mg, 9mg · ER Tab
· 8 products · General benefit · strengths: 50mg, 75mg, 100mg, 150mg, 175mg/0.875mL, 263mg/1.315mL, 350mg/1.75mL, 525mg/2.625mL · Inj Pref Syr, Inj Susp-Pref Syr
· 82 products · Listed, not a benefit (12), General benefit (70) · strengths: 1mg/mL, 0.5mg, 1mg, 2mg, 3mg, 4mg, 25mg, 37.5mg, 50mg, 0.25mg · O/L, Orally Disintegrating Tab, Pd for Inj-Vial Pk, Tab
· 2 products · General benefit · strengths: 5mg, 10mg · SL Tab
· 6 products · General benefit (3), Listed, not a benefit (3) · strengths: 25mg, 50mg, 100mg · Tab
· 2 products · General benefit · strengths: 20mg/mL, 100mg/mL · Inj Sol-1mL Amp Pk
· 2 products · General benefit · strengths: 0.5mg, 3mg · Tab
· 6 products · Listed, not a benefit (3), General benefit (3) · strengths: 1mg, 2mg, 5mg · Tab
· 14 products · Listed, not a benefit (7), General benefit (7) · strengths: 5mg/mL, 0.5mg, 1mg, 2mg, 5mg, 10mg, 20mg · Inj Sol-1mL Pk, Tab
· 8 products · Listed, not a benefit (4), General benefit (4) · strengths: 5mg, 10mg, 25mg, 50mg · Tab
Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:16:08
and 21 more